9 Late Breaking and Ongoing Trials in Nanomedicine and Tageted Delivery

Late Breaking and Ongoing Trials in Nanomedicine and Targeted Delivery

This session is dedicated to the current trends and challenges in the clinical translation of Nanomedicine as well as the potential pathways for translational development and commercialization
The speakers present late breaking and ongoing trials.

Chair: Dr. Neil Desai CEO, Aadi Bioscience Inc. Pacific Palisades, CA (USA)

Results from Clinical Phase 1 and 2 Evaluations of CPC634
Dr. Cristianne J. F. Rijcken, PharmD, PhD, Founder and CSO, Cristal Therapeutics, Maastricht (NL)

Results of a Registrational Trial of ABI-009 Nanoparticle Albumin Bound Sirolimus in Malignant PEComa and other Clinical Studies
Dr. Neil Desai, CEO, Aadi Bioscience Inc., Pacific Palisades, CA (USA)

Talidox, the World’s Smallest Liposomal Doxorubicin: Insights from First Applications in Patients and Immuno-Oncological Potential
Dr. Stefan Halbherr, PhD., CSO, Research and Development, InnoMedica Holding AG, Bern (CH)

Novel Peptide-oligonucleotide Complexes for mRNA and Gene Editing Therapeutics
Dr. Gilles Divita, Aadigen, LLC, Pacific Palisades, CA (USA) and CEO of Divincell SAS, Montpellier(F)

Clinical Experience with i.v. Liposomal Glucocorticoid Formulations Targeting Inflammation
Dr. Josbert Metselaar, PharmD, PhD, Department of Experimental Molecular Imaging, RWTH Aachen University Clinic, Aachen (D) and CEO Enceladus Pharmaceuticals, Naarden (NL)

Questions and Debate